<DOC>
	<DOCNO>NCT00960362</DOCNO>
	<brief_summary>This trial conduct North America . The aim clinical trial investigate safety , tolerability , pharmacokinetic sign bioactivity increase single dos AGS-009 patient systemic lupus erythematosus ( SLE ) .</brief_summary>
	<brief_title>An Investigation AGS-009 Patients With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Diagnosis SLE Disease duration longer equal 6 month Stable , mild moderate active SLE Receiving stable maintenance therapy Significant lupus nephritis Active central nervous system ( CNS ) disease Significant arterial venous thrombosis ( blood clot ) within 12 month prior dose Active vasculitis require treatment Body weight 120 kg History cancer Infections viral : HIV , hepatitis B C , EpsteinBarr virus ( EBV ) , cytomegalovirus ( CMV ) , varicella zoster virus ( VZV ) , herpes simplex virus ( HSV1 HSV2 ) tuberculosis ( TB ) Severe systemic microbial infection within past 12 month prior dose Immunosuppressive immune modulate therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>